Research efforts aimed at implementing liquid biopsy for early-stage cancer screening must overcome the challenge of detecting low-concentration tumor DNA fragments.
By concentrating and purifying DNA from blood samples, PHASIFY™ can improve the identification of low frequency cancer mutations.
In so doing, our technology may help to realize the promise of liquid biopsy for early-stage cancer screening.